A large pharma company requested for a comprehensive assessment on two new drug targets of interest which are the most abundantly expressed inhibitory Leukocyte immunoglobulin (Ig)-like receptors. Read how Excelra's in-depth analysis helped the pharma company facilitate early discovery phase decisions.
Client’s requirement:
Provide a holistic view of the targets coupled with comparative analysis of the targets to characterize their detailed role to facilitate early discovery phase decisions.
Our approach
The following aspects of the two targets were analyzed and compared.
- Target function in healthy tissues as well as its association with disease(s)
- Molecular pharmacology, target expression across human tissues/organs, species, gene alterations
and target interactions with other proteins/genes - ON- and OFF- target safety assessment and de-risking strategies
Competitor profile: Competitive landscape of drug development by stage (approved, clinical & pre-clinical drugs) - Recommendation of animal models and pre-clinical assays
- Adverse events or toxicity data for compounds at any stage of development
- Sequence, crystal structure, domains and homology modelling
Through this structured approach, Excelra’s team combined its expertise in Computational Biology Services and Scientific Data Management to deliver a complete comparative analysis framework.
For related work, see our case study on Identification of Predictive Biomarkers and Applications in Patient Enrichment Strategies, where biomarker insights guided clinical strategy.
